We investigated whether organ-specific differences exist in the role of inducible nitric oxide synthase (iNOS) in hyporeactivity to vasoconstrictors following 20 h in vitro exposure of isolated superior mesenteric, renal, hepatic and coronary arteries from the rat to bacterial lipopolysaccharide (LPS). LPS attenuated contraction in response to depolarizing KCl in all arteries. Maximum contractile responses to noradrenaline were attenuated in superior mesenteric and hepatic arteries, and those to the thromboxane A 2 analogue U46619 were attenuated in coronary arteries. LPS shifted the concentration-response curve to noradrenaline in renal arteries to the right. Removal of extracellular L-arginine improved the response to noradrenaline in superior mesenteric and renal arteries only. Addition of the iNOS inhibitor aminoguanidine resulted in full recovery of the responses to noradrenaline in superior mesenteric, renal and hepatic arteries. Contractile responses in coronary arteries did not improve after inhibition of iNOS activity. Therefore the pattern of the LPS-induced changes in vascular reactivity, as well as the contribution of iNOS to impaired vascular constriction, differed among vascular beds. These differences are likely to represent a contributory factor in the sepsis-associated redistribution of cardiac output.
The role of inducible nitric oxide synthase in lipopolysaccharide-mediated hyporeactivity to vasoconstrictors differs among isolated rat arteries
INTRODUCTION
Septic shock in humans is characterized by a high cardiac output and decreased systemic peripheral resistance due to dilatation of systemic resistance arteries. The excessive fall in peripheral vascular resistance causes progressive systemic hypotension that is resistant to vasoconstrictors [1] . This is associated with a redistribution of cardiac output, with an abnormal organ perfusion\demand ratio that may contribute to organ damage and failure [2] [3] [4] .
The most common cause of septic shock is infection with Gram-negative bacteria, resulting in the release of bacterial lipopolysaccharide (LPS), the toxic moiety of the outer membrane of Gram-negative bacteria, into the circulation. Stimulation of macrophages and vascular smooth muscle cells by LPS or pro-inflammatory cytokines induces the expression of an inducible isoform of nitric oxide synthase (iNOS or type II NOS), which releases massive amounts of vasodilating nitric oxide (NO) over long periods of time [5, 6] . Excessive release of NO may diminish the vasoconstrictor capacity of the vessel wall in response to endogenous or exogenous vasoconstrictors. Indeed, various studies in LPS-treated animals have provided evidence that vascular hyporeactivity to vasoconstrictors in vitro and vasopressor-resistant hypotension in vivo are related to an overproduction of NO by iNOS [7] [8] [9] [10] [11] [12] . Evidence based on the vasoconstricting effects of NOS inhibitors and elevated levels of NO metabolites in blood suggests an important role for excessive NO production in human septic shock as well [13] [14] [15] [16] [17] .
Although the general importance of iNOS in the development of cardiovascular collapse and the loss of vascular tone during sepsis and endotoxic shock has been firmly established, the observed redistribution of blood flow suggests a disparate change in tone among organ vascular beds that may not be explained by a generalized expression of iNOS. Indeed, experiments involving the treatment of experimental sepsis or endotoxaemia using adrenergic catecholamines have suggested that vasoconstrictor responses are inhibited to a greater extent in some regions than in others [18, 19] . Moreover, NO inhibition by competitive analogues of L-arginine results in enhanced vasoconstrictor responses and induces a reredistribution of blood flow [20, 21] . Non-selective NOS blockade may also have inhibited the activity of the constitutive endothelial isoform of NOS (eNOS) in these previous experiments ; however, despite this possible down-regulation of eNOS activity [22] , these findings suggest that regional differences might exist in the expression and activity of iNOS.
In the present study, we therefore focused on the development of LPS-mediated vascular hyporesponsiveness to receptor-dependent vasoconstrictors in rat arteries from different organ systems, and tested whether regional differences exist in the involvement of iNOS activity in this hyporesponsiveness, using selective iNOS blockade. In vitro experiments were performed to avoid the confounding systemic effects of LPS and anaesthesia. Arteries from the coronary, splanchnic, hepatic and renal vascular beds were chosen, since these are at risk of blood flow alterations during experimental septic shock.
METHODS

Animals and preparations of isolated arteries
All animals were treated according to national guidelines and with the permission of the Institutional Animal Care and Use Committee. Male Wistar rats (Harlan, Zeist, The Netherlands ; body weight 300-350 g ; n l 31) were anaesthetized with pentobarbital sodium (Nembutal2 ; Sanofi Sante BV, Maassluis, The Netherlands), 60 mg:kg −" intraperitoneally. Under full anaesthesia, following excision of the heart from the thorax, the mesentery (n l 8), left kidney (n l 8) or liver (n l 7) was obtained. From eight additional animals, the heart only was excised, for the isolation of coronary arteries. Tissues containing left renal, superior mesenteric, hepatic or coronary arteries were pinned in a dissecting dish containing sterile Mops buffer (4 mC) which consisted of (in mM) : NaCl 145, KCl 5.0, CaCl 02. Under sterile conditions, side branches (passive external diameter 275-350 µm) from the renal artery, superior mesenteric artery, hepatic artery and septal (coronary) artery were dissected free from surrounding tissue and cleaned of adhering fat under a stereo dissecting microscope. Dissected arteries from all four organs were cut into two 1-2-mm-long cylindrical segments that were incubated in cell culture medium according to the protocol described below.
Tissue culture
Culture plates (six wells) were filled with 3.0 ml of sterile Dulbecco's modified Eagle's medium (DMEM) containing 4 mM L-glutamine and 22.7 mM glucose. The DMEM was supplemented with 4 % (v\v) heat-inactivated fetal calf serum. The antibiotics penicillin (100 i.u.:ml −" ) and streptomycin (100 µg:ml −" ) were added to prevent bacterial growth during the incubation procedures. One segment of each isolated artery was incubated in DMEM containing LPS from Escherichia coli (50 µg:ml −" ; serotype O127 :B8), which was present throughout the incubation period ; the other segment from the same artery was incubated in the same medium without LPS and served as a time-matched control. Arterial segments were maintained for 20 h at 37 mC in an atmosphere of 95 % humidified air\5% CO # .
Isometric force measurements
Measurements of isometric force responses in isolated vessel segments were performed using the method described by Mulvany and Halpern [23] . In addition to its use in systemic vessel segments, the validity of the technique has also been demonstrated for coronary vessels [24] . Each vessel segment was suspended on two tungsten wires (50 µm diameter) inserted through the lumen. One wire was connected to a micromanipulator, whereas the other was connected to a force transducer (Kistler Morse no. 46-1003-01) configured for isometric force recordings (manufactured at the technical department of our faculty) and connected to a computer to visualize isometric force responses. Control and LPSincubated arterial segments were suspended pair-wise in a water-jacketed 10 ml organ chamber (at 37 mC), which housed both force transducers. 
Pharmacological responses
After being mounted in the myograph, segments were allowed to stabilize for 30-40 min before the study. After this stabilization period, all arterial preparations were stretched in a stepwise manner to the optimum of their length-active-tension relationship. To achieve this, the arterial preparations were first stretched by 50 µm ; when the passive force had stabilized, the arterial preparations were activated with 125 mM KCl followed by washout. This step was repeated at progressive levels of stretch until active tension induced by 125 mM KCl was at a maximum. During the rest of the experiment, vessels were kept at this optimal stretch. For all arteries, concentration-response relationships to contractile agonists were obtained by cumulative addition of small aliquots of concentrated solutions in half-exponential dose increments directly into the tissue bath ; drug concentrations were increased when the response to the preceding concentration was stable. Superior mesenteric, renal and hepatic arteries were contracted with noradrenaline (NA ; 0.01-10 µM). However, rat coronary arteries failed to respond with a stable long-lasting contraction to adrenoceptor-stimulating agents (results not shown). After the final dose of the contractile agonist, vessels were washed with fresh Krebs solution. Vessel segments were allowed to stabilize for 15 min after returning to their basal resting tension.
Concentration-response relationships to the agonists were repeated three times in different extracellular environments. First, the contractile effects of NA\U46619 were tested in the presence of 1.0 mM L-arginine. Following washout of the agonist, L-arginine was removed from the extracellular fluid and the vessels were washed three times in Krebs without L-arginine. After a 15 min restabilization period in Krebs without L-arginine, responses to NA\U46619 were repeated. After another washout, segments were incubated for 30 min with the specific iNOS inhibitor aminoguanidine (0.1 mM) in the absence of L-arginine. Following this incubation period, concentration-response relationships to NA\ U46619 were again obtained.
Drugs and chemicals
NA, U46619, L-arginine and aminoguanidine hemisulphate were obtained from Sigma Chemical Co. (St Louis, MO, U.S.A.). DMEM, fetal calf serum and penicillin\ streptomycin solution were obtained from GIBCO (Breda, The Netherlands). E. coli LPS (serotype O127 : B8) was obtained from Difco Laboratories (Detroit, MI, U.S.A.) All other chemicals were obtained from Merck (Darmstadt, Germany). Stock solutions of NA (1 mM) were freshly prepared before each experiment and placed on ice until use. U46619 was diluted in ethanol to a stock concentration of 10 mM and diluted further in deionized water to 1.0 mM. Small aliquots of this solution were kept under an argon atmosphere at k20 mC until use.
Statistical analysis
All contractile responses are expressed as force normalized to the axial segment length. In order to obtain the characteristics of the concentration-response relationships to NA and U46619, a non-linear regression fit procedure for sigmoidal concentration-response relationships was performed using a modified Hill equation :
where F max is steady-state maximum vascular constriction, [C] denotes the concentration of the agonist, the Hill coefficient (h) represents the steepness of the concentration-response relationship and EC &! represents the concentration of agonist at which force l 0.5iF max , i.e. half-maximum constriction.
Paired Student's t-tests were used to test for differences between control and LPS-incubated vessel segments after contraction with 125 mM KCl. Repeated-measures ANOVA was used to compare the cumulative concentration-response curves of control and LPS-incubated vessel segments of each vessel type. Differences in F max and EC &! between control and LPS-exposed vessels were determined using paired Student's t-tests. For comparisons between the three systemic artery types, general factorial ANOVA was performed, and the BonferroniHolm method was used to correct P values for multiple testing. P values of 0.05 were considered statistically significant. All values are expressed as meanpS.E.M. of n experiments.
RESULTS
Effects of LPS on receptor-independent vascular smooth muscle contraction
Passive tension values at optimal stretch were 224.3p 12.5, 256.0p47.0, 213.1p8.1 and 192.9p15.3 mg:mm −" in superior mesenteric, renal, hepatic and coronary arteries respectively. Exposure to LPS for 20 h did not significantly alter passive tension values at optimal stretch. Values were 209.4p12.7, 224.6p47.7, 209.0p 24.9 and 201.3p10.3 mg:mm −" in superior mesenteric, renal, hepatic and coronary arteries respectively. De- Segments from rat superior mesenteric (SMA), renal (RA), hepatic (HA) and coronary (CA) arteries were incubated for 20 h in the absence () or presence ( ) of E. coli LPS (50 µg:ml − 1 ). Force development in response to KCl is normalized to the axial segment length (mg:mm − 1 ). Data represent meansp S.E.M. of eight experiments (n l 7 for hepatic artery). Significance of differences : $ P 0.05 compared with coronary artery ; *P 0.05, F P 0.001 compared with respective control.
polarization-induced vascular contraction in response to 125 mM KCl differed among control segments from superior mesenteric, renal, hepatic and coronary arteries ( Figure 1 ) (P 0.01). Values ranged between 867.9p128.9 mg:mm −" in renal arterial segments and 423.3p48.6 mg:mm −" in coronary arterial segments. Exposure of all artery types for 20 h to LPS impaired the contractile response to 125 mM KCl ( Figure 1 ) (P 0.01). Reductions in the contractile response to KCl in LPStreated vessel segments in comparison with control segments were 51.8p9.2 %, 34.9p5.1 %, 52.7p7.0 and 64.7p6.3% in superior mesenteric, renal, hepatic and coronary arteries respectively. This decrease in contractile response differed significantly between renal and coronary arteries (P 0.05).
Effects of LPS on receptor-dependent vascular smooth muscle contraction
Cumulative concentration-response curves to NA\ U46619 are depicted in Figures 2-5 for control and LPSexposed segments of superior mesenteric, renal, hepatic and coronary arteries respectively. In each Figure, (Table 1) . LPS altered the contractile responses to NA\U46619 in the four artery types (ANOVA : P 0.05). When compared with their respective controls, the maximum contractile response to NA\U46619 was decreased in LPS-exposed superior mesenteric (Figure 2A ; P 0.005), hepatic ( Figure 4A ; P 0.005) and coronary ( Figure 5A ; P 0.005) arteries. The maximum contractile response to NA\U46619 in these arteries was reduced by 35.1p8.3 % (superior mesenteric arteries), 39.6p7.8 % (hepatic arteries) and 35.1p6.8 % (coronary arteries). EC
&!
values were unaltered in LPS-exposed segments of these arteries (Table  1) . In contrast, LPS induced a rightward shift ( Figure 3A ; ANOVA : P 0.05) of the concentration-response relationship to NA in renal arteries, so that the EC &! of the NA concentration-response relationship was increased by LPS (Table 1 ; P 0.005). The maximum contractile response to NA was not affected (Table 1) . Inducible NO synthase and vascular hyporeactivity Segments from hepatic arteries (HA) were incubated for 20 h in the absence () or presence (#) of E. coli LPS (50 µg:ml − 1 ). Concentration-response relationships were obtained consecutively in the presence of extracellular L-arginine (A), in the absence of L-arginine (B) and following incubation (in the absence of L-arginine) with aminoguanidine (AG), a specific iNOS inhibitor (C). Contractile responses are expressed as force normalized to the axial segment length (mg:mm − 1 ). Data represent meanspS.E.M. of seven experiments. Differences between concentration-response relationships in control and LPS-exposed segments were significant both in the presence (A) and in the absence (B) of L-arginine (ANOVA : P 0.05).
Figure 5 Concentration-response relationships to U46619 in coronary arteries
Segments from coronary arteries (CA) were incubated for 20 h in the absence () or presence (#) of E. coli LPS (50 µg:ml − 1 ). Concentration-response relationships were obtained consecutively in the presence of extracellular L-arginine (A), in the absence of L-arginine (B) and following incubation (in the absence of L-arginine) with aminoguanidine (AG), a specific iNOS inhibitor (C). Contractile responses are expressed as force normalized to the axial segment length (mg:mm − 1 ). Data represent meanspS.E.M. of eight experiments. Differences between concentration-response relationships in control and LPS-exposed segments were significant in the presence (A) and in the absence (B) of L-arginine, and in the presence of AG (C) (ANOVA : P 0.05). Concentration-response relationships in the absence of L-arginine L-Arginine did not alter the concentration-response relationships in control rings of the four artery types. In the absence of L-arginine, the maximum contractile response to NA was reduced by 20.0p10.3 % in LPSexposed in comparison with control superior mesenteric arteries. Although the concentration-response relationships to NA in control and LPS-exposed segments of superior mesenteric arteries did not overlap fully ( Figure  2B ), the LPS-induced attenuation of the maximum contractile response to NA in the absence of L-arginine was not significant (Table 1) . However, in renal arteries, removal of L-arginine fully reversed the LPS-induced rightward shift of the concentration-response curve to NA in the presence of L-arginine ( Figure 3B ). Hence the EC
&!
for LPS-exposed renal arteries did not differ from that for control segments (Table 1, Figure 3B ). Removal of L-arginine increased the maximum contractile response to NA in LPS-exposed segments of the hepatic artery (Table 1 ; P 0.05). Despite this increase, the maximum contractile response to NA was still attenuated by 33.7p8.8 % in comparison with that in control segments ( Figure 4B ; P 0.05). In contrast, the maximum contractile response to U46619 in LPS-exposed coronary arteries was unaltered by the removal of L-arginine (Table  1) , and thus remained attenuated in LPS-exposed coronary arteries in comparison with controls ( Figure 5B ; P 0.05).
Concentration-response relationships in the presence of aminoguanidine
When compared with concentration-response relationships in the absence of L-arginine, incubation of LPSexposed superior mesenteric arteries with aminoguanidine led to a significant increase in the maximum contractile response (Table 1 ; P 0.001). This resulted in the full recovery of the maximum vasocontractile response to NA ( Figure 2C ). In addition, as was the case in the absence of L-arginine, no significant differences were detected between control and LPS-exposed renal segments following exposure to aminoguanidine ( Figure  3C ). Incubation with aminoguanidine increased (Table 1 ; P 0.05) the maximum contractile response to NA in LPS-exposed hepatic arteries, while having no effect in controls. Although concentration-response relationships to NA did not overlap fully ( Figure 4C ), no differences could be detected in the overall concentration-response relationships between control and LPS-exposed hepatic arteries after incubation with aminoguanidine. In coronary arteries, incubation with aminoguanidine did not improve vascular contractility in LPS-exposed as compared with control segments ( Figure 5C ; ANOVA : P 0.05). The maximum contractile responses to U46619 remained decreased in LPS-exposed segments ( Figure  5C ; P 0.01).
DISCUSSION
A 20 h exposure of isolated rat arteries from different organs at risk from blood flow alterations during endotoxin shock to E. coli LPS resulted in a regionally varying impairment of vascular smooth muscle contraction in response to receptor-independent and receptor-dependent agonists, while passive smooth muscle properties remained unaltered. Furthermore, regional differences in the role of iNOS in the LPS-mediated impairment of vascular smooth muscle contractions were found. Hyporeactivity to NA was fully reversed after inhibition of iNOS in superior mesenteric, renal and hepatic arteries. In contrast, impaired constriction to the thromboxane A # analogue U46619 in coronary arteries was not improved after inhibition of iNOS activity. These results indicate a differential role for iNOS in the alteration of vascular smooth muscle contractile function by LPS.
In contrast with eNOS (type III NOS), the iNOS isoform is a high-output isoform of the enzyme that is strongly dependent on the presence of extracellular Larginine [25] [26] [27] . L-Arginine availability may even become a rate-limiting step in iNOS activity [28] [29] [30] [31] . For this reason, the role of iNOS in different vascular tissues was tested in two steps. Initial measurements of vascular smooth muscle function in the presence of L-arginine were repeated in the absence of L-arginine. Finally, in the absence of L-arginine, iNOS was inhibited using the specific iNOS inhibitor aminoguanidine [32] [33] [34] .
Removal of L-arginine from the extracellular fluid did not affect vascular smooth muscle responses to NA\ U46619 in control arteries. Whereas the removal of Larginine from the extracellular fluid fully reversed the effects of LPS in rat renal arteries, maximum contractile responses in rat hepatic arteries remained attenuated. In superior mesenteric arteries, an intermediate situation was found. Although the concentration-response relationships did not overlap fully, a recovery was observed in the maximum contractile response to NA in LPSexposed superior mesenteric arteries, which was no longer different from that in controls. The finding that removal of L-arginine improves vascular contractility has been confirmed by other in vitro studies [26, 27] , and demonstrates the importance of a continuous L-arginine supply for realization of the full effects of iNOS activity.
Incubation with aminoguanidine fully reversed hypocontractility induced by LPS in superior mesenteric and hepatic arteries to control levels. Both the effects of removal of L-arginine and the effects of aminoguanidine indicate a principal role for iNOS in LPS-mediated impairments of vascular smooth muscle function in these systemic vessels. However, neither removal of Larginine nor incubation with aminoguanidine improved LPS-induced hyporeactivity to U46619 in rat coronary arteries.
In contrast with the other arteries tested, which showed an LPS-mediated decline in contractile capacity in response to NA, as well as in depolarization-induced constriction due to high K + , rat renal arteries displayed decreased sensitivity to NA, i.e. a rightward shift of the concentration-response relationship, with an unaltered maximum contractile capacity. Constriction by high K + was decreased, as in the other arteries, although to a lesser extent. Nevertheless, LPS-mediated desensitization to NA was fully dependent on iNOS-derived NO, since removal of L-arginine fully reversed the effects of LPS. This raised the question of why the concentrationresponse relationships to NA in different vascular beds were affected differentially by NO, whereas receptorindependent vasoconstriction was decreased similarly in all arteries. Although a relatively low degree of iNOS induction in the kidneys of septic animals has been reported [35] [36] [37] in comparison with that in other organs, differences in the amount of local NO release cannot fully explain the different effects of LPS in systemic vessels alone, since this would imply a similar pattern, but a different magnitude, of LPS-induced hyporeactivity to NA, which was not the case in our study. Alternatively, the rightward shift of the concentration-response relationship to NA in renal arteries suggests a decrease in the Ca# + sensitivity of the contractile myofilaments in renal artery smooth muscle cells, whereas the decrease in maximal contractile capacity in the other arteries rather suggests a (reversible) deficiency of [Ca# + ] i . Two major mechanisms are acknowledged by which NO counteracts vasocontractile mechanisms : first by a decrease in [Ca# + ] i through a diverse array of ion channel and ion pumpdependent effects, and secondly by a decrease in Ca# + sensitivity via an increase in myosin phosphatase activity, thereby decreasing the levels of phosphorylated myosin light chain in smooth muscle cells [38, 39] . Tissue differences among organ arteries in the balance of these two processes that mediate the effects of iNOS-derived NO on receptor-mediated vasoconstriction may therefore explain in part the differences found between the arterial types tested. The finding that the LPS-induced decrease in contraction induced by high K + , which operates mainly through a depolarization-induced increase in [Ca# + ] i , was less in renal arteries than in the other arteries further supports the contention that the cellular mechanisms that contribute to the NO-mediated decrease in [Ca# + ] i may be less important in renal arteries than in the other arteries tested. A predominance of (induced) NO in the mediation of decreased Ca# + sensitivity in renal arteries, possibly acting in concert with the reported tissue differences in the amount of NO produced [35] [36] [37] , may explain the rightward shift of the NA concentrationresponse curve in the renal arteries, which contrasted with the defective maximal contractile capacity in the other arteries.
A complicating factor in our study is that two different receptor-dependent vasoconstrictors were used. NA did not induce stable constriction in coronary arteries, whereas a stable constriction was achieved with this agent in the other arteries. Therefore U46619 was used to constrict vascular smooth muscle in coronary arteries, and NA was used in the other arteries. It is conceivable that iNOS-mediated NO release only affects contractile responses induced by NA, and not those induced by U46619. This might provide an explanation for the lack of effect of aminoguanidine in reversing LPS-induced hyporeactivity to U46619 in coronary arteries. However, U46619 induces vascular smooth muscle contraction via similar signal transduction mechanisms as the adrenoceptor agonists NA and phenylephrine [40] . Furthermore, the endothelium-dependent vasodilator acetylcholine, which induces dilation via endothelial NO release, does relax U46619-preconstricted coronary arteries (H. A. Piepot, A. B. J. Groeneveld, A. A. van Lambalgen and P. Sipkema, unpublished work). Finally, in various types of arteries, including coronary arteries, LPS-mediated defects in contractile responses to U46619 were reversed after inhibition of NO synthesis [17, 41, 42] . From these findings, we conclude that the inability of aminoguanidine to reverse LPS-induced hypocontractility to U46619 is not caused by an inherent difference in the sensitivity of NA and U46619 to be affected by NO synthesis. Therefore the apparent lack of a role for iNOS in LPSmediated coronary vascular smooth muscle hypocontractility may not have been caused by the use of U46619 as a vasoconstrictor.
The results presented in this paper contrast with the reported iNOS-mediated increases in coronary blood flow and impaired pressor responses to receptor-dependent vasoconstrictors, including U46619, in intact heart preparations [42, 43] . In addition, several studies have detected increased iNOS mRNA levels and activity in myocardial tissue after treatment with LPS [35, 44] . Therefore NO derived from myocardial iNOS may have contributed to blood flow alterations and impaired pressor responses in the aforementioned experiments [42, 43] . However, the present results demonstrate vascular dysfunction in coronary arteries independently of potential myocardium-derived NO. Therefore other endogenous vasodilatory factors seem to be produced in the coronary artery following long-term exposure to LPS. A possible candidate may be the production of vasodilatory prostanoids derived from increased cyclooxygenase-2 activity due to LPS [17] .
In conclusion, the present study has documented regional differences in the effects of LPS on vascular reactivity. In addition, the differential role of iNOSderived NO in different vascular tissues may constitute an important contributory factor to the redistribution of blood flow that occurs during septic shock.
